TRANSFORMING BRONCHOSCOPY
Reach. Vision. Control.
The MONARCH® Platform integrates a variety of technologies designed to empower physicians with greater reach, uninterrupted vision, and meticulous control. The Monarch® Platform maintains vision throughout the procedure, especially during the most critical step - the biopsy. Learn More About the MONARCH® Platform
ATS Webinar- Impact of a Robotic-Assisted Bronchoscopy Program
Hear Drs. Kyle Hogarth and Susan Garwood share their firsthand experience using the first robotic-assisted bronchoscopy platform and how they built their MONARCH® Program in both the academic and community settings.
The Value of Vision in Diagnosing Peripheral Lung Lesions
Webinar that features Dr. Khan and Dr. Kovacs presenting on the importance of vision while sampling peripheral lung lesions and how the MONARCH® Platform has impacted their patients and practice.
Lung Cancer Initiative
The Lung Cancer Initiative at Johnson & Johnson (LCI) is dedicated to transforming the standard of care for this devastating disease. Leveraging Johnson & Johnson's expertise across its Consumer, Medical Device and Pharmaceutical business segments, the vision for the LCI is to develop solutions that prevent, intercept and cure lung cancer, enabling a future vision where there is a world without this devastating disease.
Fellows Hands-On Program
Fellows Brochure
Learn more about our Fellows Hands-on Program.
MONARCH® Mobile Lab
The MONARCH® Mobile Lab hits the road this year, bringing an exclusive hands on experience of the world’s market-leading Robotic-Assisted Bronchoscopy Platform to a city near you. Contact your Auris Sales Representative for more information.
Lung Nodule Evaluation Using Robotic-Assisted Bronchoscopy at a Veteran’s Affairs Hospital
Abstract:
The incidence of lung nodules has increased with improved diagnostic imaging and screening protocols. Despite improvements for diagnosing pulmonary nodules with technologies such as electromagnetic navigational bronchoscopy (ENB), several limitations still exist including adequate visualization, localization, and diagnostic yield. Robotic-assisted bronchoscopy with ENB has been introduced as a method to overcome these shortcomings. We describe our initial experience in evaluating lung nodules with robotic assisted bronchoscopy. We retrospectively reviewed data on the first 25 patients that underwent robotic-assisted bronchoscopy and biopsy. We analyzed successwith localization, diagnostic yield, and post procedural morbidity. Diagnostic yield was 96% (24/25) with no periprocedural morbidity. The majority of nodules were malignant or atypical (76%) and were located in the right upper lobe. Diameter ranged between 0.8–6.9 cm (median size 1–2 cm). Seventy-five percent of patients underwent subsequent treatment for cancer based on these results, with 25% having continued surveillance. Robotic assisted bronchoscopy is safe and accurate. Studies with larger numbers will allow better understanding of the diagnostic yield and clinical utility of this approach in comparison to other diagnostic tools for lung nodules.
